Greenwich LifeSciences (GLSI) to Release Earnings on Monday

Greenwich LifeSciences (NASDAQ:GLSI) is projected to announce its earnings results before the market opens on Monday, April 21st. Analysts expect the company to announce earnings of ($0.21) per share for the quarter.

Greenwich LifeSciences Stock Up 5.8 %

Shares of GLSI opened at $9.86 on Monday. The business has a 50-day simple moving average of $11.21 and a two-hundred day simple moving average of $12.53. The stock has a market cap of $129.61 million, a price-to-earnings ratio of -12.32 and a beta of 1.76. Greenwich LifeSciences has a 52 week low of $8.06 and a 52 week high of $18.75.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $38.00 price target on shares of Greenwich LifeSciences in a research note on Tuesday, February 11th.

Insider Buying and Selling at Greenwich LifeSciences

In other news, CEO Snehal Patel bought 3,600 shares of the firm’s stock in a transaction that occurred on Monday, April 7th. The shares were bought at an average cost of $9.10 per share, for a total transaction of $32,760.00. Following the completion of the transaction, the chief executive officer now owns 5,561,602 shares of the company’s stock, valued at approximately $50,610,578.20. This represents a 0.06 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 51.67% of the company’s stock.

Institutional Trading of Greenwich LifeSciences

An institutional investor recently raised its position in Greenwich LifeSciences stock. Bank of America Corp DE increased its holdings in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) by 22.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 7,262 shares of the company’s stock after purchasing an additional 1,322 shares during the period. Bank of America Corp DE owned approximately 0.06% of Greenwich LifeSciences worth $82,000 at the end of the most recent quarter. 4.16% of the stock is owned by institutional investors.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.